GlassScriptPhysician profile
Brian Leonard Erlich
NPI 1639172547
$1,582.25
in general payments reported to CMS, 2019-2025
12 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $35.62 · 2021: $241 · 2022: $424 · 2023: $63.53 · 2024: $297 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399 · Education: $99.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.71 |
| Education | $99.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $466.51 | 2022-2024 | Nxstage System One, Liberty Select Cycler |
| Astrazeneca Pharmaceuticals LP | $297.02 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $229.20 | 2019-2022 | |
| Novo Nordisk INC | $122.21 | 2025 | |
| Horizon Therapeutics Plc | $112.86 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $95.51 | 2021 | |
| Fresenius USA Marketing, INC. | $84.15 | 2020-2024 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $72.45 | 2024 | Tavneos |
| Calliditas Therapeutics US INC. | $38.90 | 2022-2023 | Tarpeyo |
| Akebia Therapeutics INC | $33.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.29 | 2024 | |
| Mallinckrodt Enterprises LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Erlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.